Subscribe To
ELYM / Eliem Therapeutics to Present at Stifel's 2022 CNS Days
ELYM News
By Zacks Investment Research
July 21, 2023
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises more_horizontal
By InvestorPlace
July 20, 2023
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. more_horizontal
By Market Watch
July 20, 2023
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal ex more_horizontal
By GlobeNewsWire
November 30, 2022
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology compa more_horizontal
By GeekWire
April 25, 2022
Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic
Shares of Eliem Therapeutics fell more than 50% Monday after reporting disappointing clinical data. more_horizontal
By Benzinga
April 25, 2022
See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting
Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve statistically signif more_horizontal
By GlobeNewsWire
March 21, 2022
Eliem Therapeutics to Present at Stifel's 2022 CNS Days
SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology comp more_horizontal